ストックスクリーナーアプリを入手
25.64
1.42%
-0.37
アフターアワーズ：
25.31
-0.33
-1.29%
前日終値:
$26.01
開ける：
$25.43
24時間の取引高:
1.15M
Relative Volume:
1.16
時価総額：
$2.88B
収益：
$454.68M
当期純損益:
$-178.68M
株価収益率:
-15.82
EPS:
-1.6209
ネットキャッシュフロー:
$-135.66M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+33.40%
6か月 パフォーマンス:
+32.37%
1年 パフォーマンス:
-26.83%
1日の値動き範囲:
$25.25
$25.96
1週間の範囲:
$24.64
$27.50
52週間の値動き範囲:
$15.96
$35.45
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Compare ZLAB vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
25.64 | 2.92B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-14 | 開始されました | Morgan Stanley | Overweight |
| 2023-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 開始されました | Macquarie | Outperform |
| 2021-10-12 | 開始されました | Bernstein | Mkt Perform |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-04-15 | 開始されました | Guggenheim | Buy |
| 2019-07-12 | 開始されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
| 2019-01-29 | 開始されました | Credit Suisse | Outperform |
| 2018-11-21 | 開始されました | Jefferies | Buy |
| 2018-06-21 | 再開されました | Leerink Partners | Outperform |
| 2018-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 開始されました | JP Morgan | Neutral |
| 2017-10-16 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Zai Lab Limited Adr (ZLAB) 最新ニュース
Former Zai Lab (NASDAQ: ZLAB) executive lines up multi-million ADS sale - Stock Titan
Zai Lab (NASDAQ: ZLAB) holder lines up Aug. 19 ADS sale after recent trades - Stock Titan
Zai Lab (ZLAB) Posts Positive Phase 3 Results In Autoimmune Myositis - Sahm
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Business Wire
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock - MarketBeat
William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case? - Sahm
Zai Lab (NASDAQ:ZLAB) Shares Gap DownWhat's Next? - MarketBeat
Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ - Stock Titan
ZLAB (NASDAQ: ZLAB) filer plans sale of 619 American Depositary Shares - Stock Titan
Zai Lab (ZLAB) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen - Sahm
Zai Lab Q2 Earnings Call Highlights - finance.yahoo.com
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Form 8K ZAI LAB LIMITED For: 6 August By Investing.com - Investing.com Nigeria
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings - MarketBeat
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M - Stock Titan
Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M - Stock Titan
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab’s zoci targets previously treated neuroendocrine cancers - Stock Titan
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) - Business Wire
Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday - MarketBeat
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
ZLAB|Zai Lab Ltd|Price:23.320|Chg%:+2.440 - TradingKey
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
A2DX1V Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 - BioSpace
Zai Lab schedules an Aug. 6 webcast and call for Q2 results - Stock Titan
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Zai Lab and Boehringer Advance New Immunotherapy Combo in Small Cell Lung Cancer - TipRanks
Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) CEO Du Ying gains ADSs from RSU awards and tax withholding - Stock Titan
ZLABZai Lab Limited ADR Options - Finviz
Zai Lab stock keeps its listing focus. Investors watch the US ADR profile. - Ad-hoc-news.de
Zai Lab (ZLAB) CEO sells ADS to cover taxes after RSU vesting - Stock Titan
Form 144 Zai Lab Ltd For: 30 June By Investing.com - Investing.com Nigeria
ZLAB (NASDAQ: ZLAB) insider resale planned on 06/29/2026; recent ADS sales reported - Stock Titan
Zai Lab (ZLAB) legal chief settles RSUs, sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CEO sells ADSs after RSU vesting and tax cover - Stock Titan
CFO equity transactions at Zai Lab (ZLAB) show RSU vesting and tax sale - Stock Titan
Zai Lab ADR outlines oncology pipeline priorities, shares tied to upcoming data - ad-hoc-news.de
1ZL Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (GETTEX:1ZL) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (LS:A2DX1V) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ZLAB) - TradingView
Form 144 Zai Lab Ltd For: 26 June - Investing.com South Africa
Zai Lab Limited Adr (ZLAB) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):